pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,695 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1894Endpoints1467Fierce Biotech779BioSpace768BioPharma Dive555raps257onclive165fda recalls126
therapy area
allOncology13097Rare Disease3399Immunology3069Cardiology2870Hematology2337Pulmonology2300Vaccines
  • FDA rejects Capricor's Duchenne cell therapy again, citing major trial flaws
    Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
    Endpoints · 13h agoRegulatoryNegative↗ source
  • Biopharma newsletter released despite tech outages, highlights Washington political news
    The latest edition of a biopharma newsletter was published even though the week was marked by several technology outages. The issue notes that the most significant story came from Washington, wher…
    Endpoints · 3h agoNeutral↗ source
← prev
page 1 of 148
next →
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Capricor’s regulatory odyssey for DMD cell therapy hits second FDA rejection
    A new proposed indication was not enough to get deramiocel across the regulatory finish line. The FDA has again turned away the cell therapy, which is being developed for Duchenne muscular dystroph…
    BioSpace · 56m ago↗ source
  • RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer data
    RevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory market
    Analysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…
    BioSpace · 1d agoDealPositive↗ source
  • Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
    Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapy
    Compass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…
    BioPharma Dive · 19h agoRegulatoryNeutral↗ source
  • Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trial
    Erasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…
    BioPharma Dive · 21h agoPositive readoutNeutral↗ source
  • Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competition
    Revolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…
    Endpoints · 22h agoPositive readoutNeutral↗ source
  • Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancer
    Merck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…
    Endpoints · 23h agoPositive readoutPositive↗ source
  • Merck-Kelun ADC sac-TMT shows overall survival benefit in Phase 3 stomach cancer trial
    Merck, licensing the TROP2-targeting antibody drug conjugate sac-TMT from Kelun-Biotech, reported that the therapy improved overall survival in patients with advanced gastroesophageal adenocarcinom…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slump
    Biotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
    BioPharma Dive · 1d agoDealNeutral↗ source
  • Greenwich Rx voluntarily recalls compounded sterile products over sterility concerns
    Greenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, announced a voluntary nationwide recall of certain compounded sterile product lots that are still within their beyond-use dates.…
    fda recalls · 15h agoCRLNegative↗ source
  • Lawmakers split on US restrictions for China biotech investments
    Ahead of the upcoming Democrat-controlled Congress, lawmakers from both parties are articulating new positions on whether the United States should limit investments in China's rapidly growing biote…
    Endpoints · 19h agoRegulatoryNeutral↗ source
  • FDA delays decision on Savara's rare lung disease therapy, pushing back deadline
    The FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…
    BioSpace · 22h agoRegulatoryNegative↗ source
  • Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filing
    Celldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
    BioPharma Dive · 1d agoNegative readoutNegative↗ source
  • Celldex drops eczema antibody barzolvolimab after Phase 2 failure
    Celldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…
    Endpoints · 1d agoNegative readoutNegative↗ source
  • FDA delays decision on Belite Bio's Stargardt disease drug to May 12
    The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
    Fierce Biotech · 1d agoRegulatoryNeutral↗ source
  • Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitis
    Both Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
    Fierce Biotech · 1d agoNegative readoutNegative↗ source
  • Novo announces layoff of 215 New Jersey staff as Bausch + Lomb trial misses endpoint
    Novo Pharma said it will cut 215 positions at its Plainsboro, New Jersey facility, with the reductions slated to begin in February 2027. The move adds to a series of recent workforce reductions ac…
    Endpoints · 22h agoLayoffsNegative↗ source
  • Teva appoints interim R&D head as Eric Hughes departs
    Teva announced that its global research and development leader and chief medical officer, Eric Hughes, has left the company. Hughes, who joined Teva in 2022 after a senior role at Vertex, will be s…
    Endpoints · 1d agoNeutral↗ source
  • CNS players discuss deals, psychiatry challenges and Alzheimer focus at Jefferies London conference
    The Jefferies Global Healthcare conference in London brought together several companies active in the central nervous system and psychiatry sectors. Attendees heard updates from a range of drugmake…
    Endpoints · 1d agoNeutral↗ source
  • ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loom
    As the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.
    Fierce Biotech · 1d agoNeutral↗ source
  • Shanghai San Niu recalls Evergreen and Salt-and-Pepper Soda biscuits over undeclared milk and shrimp allergens
    Shanghai San Niu Food Co., Ltd. announced a recall of all Sanniu Evergreen Biscuits and Sanniu Salt-and-Pepper Soda Biscuits after testing indicated the presence of undeclared milk in the former an…
    fda recalls · 21h agoCRLNegative↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 23h agoLayoffsNegative↗ source